– UK, Oxford – Physiomics plc (LON: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalized medicine solutions, today announced the appointment of current COO Dr. Peter Sargent to its Board of Directors as CEO, while Dr. Jim Millen is moving to the Non-Executive Chairman role with immediate effect.
“Since joining the Company last September, Pete has demonstrated to me and the Board that he has the skills, experience, attitude and vision to help us achieve our strategic goals. I look forward with optimism to what we can achieve under Peter’s executive leadership and to continuing to work closely with him in our new roles,” said Board Chairman, Dr. Jim Millen.
About Dr. Peter Sargent
Dr. Peter Sargent joined the Company in September 2023 as COO and has quickly proved invaluable in helping to drive the business development agenda, supporting the technical team, and developing our overall strategy. He has worked closely with Dr. Millen over the last five months and has already taken on responsibility for many of the activities that will be at the core of his new, expanded role.
Before joining Physiomics in September 2023, Dr. Sargent held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH), leading large teams of professionals and servicing a variety of clients in the biopharmaceuticals space. Among his other previous roles, Dr. Sargent has also been Head of Business Development for the UK’s National Institute for Health and Care Research, leading a team supporting global life science businesses’ access to funding and research infrastructure in the UK.
Dr. Peter Sargent said: “I am thrilled to take on the role of CEO and director of Physiomics. Having had time to get to know the business and meet many of our clients and partners over these last few months, I can see many exciting opportunities ahead for us. I look forward to speaking to shareholders next week and over the course of 2024.”
About Dr. Jim Millen
Dr. Jim Millen has acted as Executive Chairman and CEO since February 2022, and he will remain closely involved as Non-Executive Chairman.
About Physiomics plc
Physiomics is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalized medicine solutions. The Company’s Virtual Tumour™ technology uses computer modeling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies has been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co, and Bicycle Therapeutics.
SOURCE: https://www.physiomics.co.uk/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
